Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Spyglass Capital Management's investment thesis on Ascendis Pharma A/S ($ASND) — Q3 2025 | Buyside Digest

All Pitches

View Letter Analysis

$ASNDNASDAQAscendis Pharma A/S

BULL

Spyglass Capital Management—ASND

Fund Letter

Q3 2025

Published September 30, 2025

View Fund Profile

$247.91USD

-8.4% vs last month

$204.05Pitched

+21.5% since pitch

Market Cap$16.3B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

The manager re-entered Ascendis Pharma following the incredibly successful US commercial launch of Yorvipath for hypoparathyroidism. Yorvipath enjoys monopoly...

— Spyglass Capital Management

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $ASND, and what else Spyglass Capital Management is buying.

Other pitches on $ASND

Other investors who've written on Ascendis Pharma A/S

No other institutional pitches found for this ticker yet.

View all $ASND pitches →